Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)

Summary

Single arm phase I/II study of ixazomib and romidepsin in relapsed/refractory PTCL. Each cycle is 28 days. Patients will continue to receive therapy until progressive disease, unacceptable toxicity, or if any other withdrawal criteria are met. The phase I study includes three dose levels. The phase II study will include treatment with ixazomib and romidepsin at the MTD established in the Phase I study.

Timeline

Start

2018-09-26

Primary completion

2020-08-27

Completion

2020-08-27

Drugs

Indications